research animal models

ORIGIN
LCAT mice were developed by injecting a 7.6 kb DNA fragment containing the entire human LCAT (lecithin-cholesterol acyltransferase) gene, 550 bp of a 3’ untranslated region and the murine albumin promoter and enhancer sequences into pronuclei of 1-day-old superovulated female C57BL/6 embryos. Founders were identified by PCR amplification and confirmed by Southern blot using a full-length cDNA probe. Founder mice were bred to C57BL/6 mates to identify germline transmission and transgenic offspring were used to maintain the transgenic line. Transferred to Charles River under exclusive license in 2011.

STRAIN CODE
Coming Soon

COAT COLOR
Black

MUTATION INFORMATION
LCAT is a key enzyme in humans in the plasma metabolism of cholesterol and is thought to play a role in reverse cholesterol transport.

Features of the Model

• HDL is more efficient than control mice in the efflux of cholesterol from human skin fibroblasts.
• Esterification of cellular cholesterol is markedly increased.
• Rate of clearance of cholesteryl ester was similar in transgenic and control mice, but the HDL cholesteryl ester transport rate was significantly increased in the transgenic mice.
• Uptake of cholesteryl ester in the liver was also significantly increased compared to the control.

It is postulated that LCAT modulates the rate by which cholesterol is effluxed from cell membranes onto HDL, esterified, transported and taken up into the liver.

RESEARCH APPLICATION
Cholesterol efflux, esterification and transport

ORDERING INFORMATION
Please call 1.800.LAB.RATS if you would like to place an order.

For additional information about LCAT mice, please contact Technical Services at 1.877.CRIVER.1 (1.877.274.8371) or askcharlesriver@crl.com.

DISCLAIMER
LCAT mice may be subject to the licensed patents and are sold only for research purposes under agreement from Pfizer, Inc.